The objective of this study is to allow treatment with the sirolimus-eluting Bx VELOCITYTM stent in patients with a serious disease or condition for which there is no generally acceptable alternate treatment available.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
252
CYPHER Sirolimus-Eluting Coronary Stent
Scripps Clinic and Research
La Jolla, California, United States
The primary endpoint of this study is a composite of Target Vessel Failure (TVF) defined as target vessel revascularization, myocardial infarction or cardiac death at 30 days, 6mo, 12mo, 2, 3, 4, and 5 years.
Time frame: 30 days, 6mo, 12mo, 2, 3, 4, and 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.